PMID- 11515819
OWN - NLM
STAT- MEDLINE
DCOM- 20020122
LR  - 20201226
IS  - 1567-5769 (Print)
IS  - 1567-5769 (Linking)
VI  - 1
IP  - 8
DP  - 2001 Aug
TI  - Interferon gamma-producing ability in blood lymphocytes of patients with lung 
      cancer through activation of the innate immune system by BCG cell wall skeleton.
PG  - 1559-69
AB  - An in vitro assay system was developed to assess the potency of the human innate 
      immune system by measurement of IL-12, IL-18, IL-10 and IFNgamma in the 
      supernatants of bacillus Calmette-Guerin cell wall skeleton (BCG-CWS)-stimulated 
      blood samples. BCG-CWS is a ligand for Toll-like receptor (TLR) 2 and 4, and 
      activates monocytes to macrophages (Mphi), and immature dendritic cells to mature 
      antigen-presenting cells (APC). This system was found to allow the discrimination 
      of immune suppressive states in patients with lung cancer from normal immune 
      states in light of the cytokine profile. The following results were deduced from 
      analyses of BCG-CWS-stimulated blood samples of lung cancer patients with 
      reference to normal subjects. (1) The levels of production of IFNgamma and IL-10 
      by lymphocytes were decreased. (2) IL-12 p40 production by monocytes/Mphi was 
      upregulated, while that of IL-10 was downregulated. (3) IL-18 was detected in all 
      patients in a range similar to normal subjects. (4) Responses of lymphocytes to 
      IL-2 and IL- 18 in terms of IFNgamma production were diminished. (5) The 
      upregulated IL-12 levels were recovered to within the normal range in most 
      patients after tumor resection. (6) Male patients showed more severe suppression 
      of IL-12/IL-18-mediated IFNgamma production than female patients. Thus, the 
      lesser IFNgamma production observed in patients' blood with high IL-12 p40 levels 
      in response to BCG-CWS may reflect the production of p40 dimers or IL-23 instead 
      of p70, or the presence of some unknown pathways to prohibit the interface 
      between the innate and acquired immune systems. BCG-CWS-mediated Toll signaling 
      may participate in IFNgamma induction for lymphocytes through Mphi/APC IL-12/I-18 
      modulation.
FAU - Matsumoto, M
AU  - Matsumoto M
AD  - Department of Immunology, Osaka Medical Center for Cancer and Cardiovascular 
      Diseases, Japan.
FAU - Seya, T
AU  - Seya T
FAU - Kikkawa, S
AU  - Kikkawa S
FAU - Tsuji, S
AU  - Tsuji S
FAU - Shida, K
AU  - Shida K
FAU - Nomura, M
AU  - Nomura M
FAU - Kurita-Taniguchi, M
AU  - Kurita-Taniguchi M
FAU - Ohigashi, H
AU  - Ohigashi H
FAU - Yokouchi, H
AU  - Yokouchi H
FAU - Takami, K
AU  - Takami K
FAU - Hayashi, A
AU  - Hayashi A
FAU - Azuma, I
AU  - Azuma I
FAU - Masaoka, T
AU  - Masaoka T
FAU - Kodama, K
AU  - Kodama K
FAU - Toyoshima, K
AU  - Toyoshima K
FAU - Higashiyama, M
AU  - Higashiyama M
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (BCG Vaccine)
RN  - 0 (Cell Wall Skeleton)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
EIN - Int Immunopharmacol 2002 Apr;2(5):731. Takami, H [corrected to Takami, K]
MH  - Adjuvants, Immunologic/*pharmacology
MH  - Adult
MH  - Aged
MH  - BCG Vaccine/*immunology/pharmacology
MH  - Cell Wall Skeleton/immunology/*pharmacology
MH  - Female
MH  - Humans
MH  - Immune System/drug effects/*metabolism
MH  - Interferon-gamma/*biosynthesis/blood
MH  - Lung Neoplasms/blood/*immunology
MH  - Lymphocytes/blood/drug effects/*immunology
MH  - Male
MH  - Middle Aged
MH  - Patients
EDAT- 2001/08/23 10:00
MHDA- 2002/01/23 10:01
CRDT- 2001/08/23 10:00
PHST- 2001/08/23 10:00 [pubmed]
PHST- 2002/01/23 10:01 [medline]
PHST- 2001/08/23 10:00 [entrez]
AID - S1567576901000716 [pii]
AID - 10.1016/s1567-5769(01)00071-6 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2001 Aug;1(8):1559-69. doi: 10.1016/s1567-5769(01)00071-6.